Binge Eating Disorder Market Size, Share and Global Trend By Drug Class (Antidepressant, Anticonvulsant, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Regional Forecast, 2024-2032

Binge eating disorder (BEG) is a medical disorder in which the individual consumes large amounts of food and is unable to control the excessive feeding. The individuals diagnosed with binge eating disorder are often overweight or obese, but can also exhibit normal weight profiles and suffer from the compulsion to binge eat. The symptoms of binge eating disorder include consumption of large amounts of food over a two-hour period, feelings of guilt & depression, secretive consumption of food, eating till uncomfortably full and frequent dieting with no weight loss.

Individuals at risk of binge eating disorder include those with familiar history, frequent dieters and prevalence of psychological issues. Medical complications of binge eating disorder include cardiac diseases, obesity and related complications such as type 2 diabetes, insomnia & gastroesophageal reflux disease and depression.

To gain extensive insights into the market, Request for Customization

The growth of the global binge eating disorder is attributed to a number of factors such as increased prevalence of eating disorder, increasing incidence of obesity and associated comorbidity and large pool of patients suffering from binge eating disorder in emerging countries.

According to studies conducted by the research journals such as Biological Psychiatry, Psychiatry Research & Comparative Effectiveness Review, 8.0% of individuals in the U.S. suffer from binge eating disorders in their lifetime and nearly half of the individuals diagnosed with binge eating disorder have a comorbid mood disorder.

These trends combined with the other factors are expected to drive the market growth. The factors limiting the growth of global binge eating disorder market are the side effects associated with the treatment options, lack of awareness and stigma associated with binge eating disorder among patients in emerging countries.

Key Players Covered

Some of the major companies operating in the global binge eating disorders market are Takeda Pharmaceutical Company Limited, Sunovion Pharmaceuticals Inc., H. Lundbeck A/S, Orexigen Therapeutics, Inc., Novo Nordisk A/S, Eli Lilly and Company, Jazz Pharmaceuticals Inc., and VIVUS Inc.

SEGMENTATION

Key Insights

• Pipeline Analysis


• Prevalence of eating disorders by key countries


• Emerging novel therapeutics for binge eating disorders


• Key mergers and acquisitions

Regional Analysis

Geographically, the global binge eating disorder market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global binge eating disorder market in 2018 due to the increasing prevalence of binge eating disorders, established healthcare system, access to advanced and novel therapeutics, greater demand for mental health wellness and increasing incidence of associated comorbidities. According to research conducted by Mental Health America in U.S around 20 million women and 10 million men suffer from a clinically significant eating disorder at some phase in their life. Asia Pacific is the fastest emerging market due to increasing prevalence of eating disorders, increasing disposable incomes, developing healthcare system, reduction of stigma associated with treatment options and increasing awareness of psychological wellbeing.

Key Industry Developments

• In October 2018, UNC School of Medicine and Recovery Record launched a study using the Recovery Record app and Apple watch to detect and prevent binge eating behaviour in people suspected with binge eating disorder (BED).
• In July 2018, Drexel university at its West Philadelphia campus announced the launch of new outpatient clinic for patients with eating disorder and weight management problems.
• In May 2016, researchers at the University of Alabama at Birmingham discovered that transcranial direct current stimulation (tDCS) which was earlier used in treatment of depression, Parkinson’s disease and autism is also effective in treatment of binge eating disorder (BED).
• In January 2015, the Food and Drug Administration (FDA) approved Vyvanse (lisdexamfetamine dimesylate), an oral central nervous system (CNS) stimulant for treatment of adults with binge eating disorder (BED).